Profilepicture Ingrid Glimelius

Ingrid Glimelius

Affiliated to research

About me

I am a professor in Oncology and a medical oncologist working with mainly lymphoma- and testicular cancer patients at Uppsala University Hospital and do research at both Karolinska Institutet and Uppsala University,…. I have been collaborating with Karin E Smedby and been affiliated to the Cancer Epidemiology group at the Division of Clinical Epidemiology, Karolinska Institutet since long. In addition to my clinical work I perform clinical phase I-III studies and epidemiological studies. I supervise PHD-students and post docs and I teach both medical students and senior physicians. I have been awarded Senior Clinical Investigator Cancer Award from the Swedish Cancer Society in spring 2019.

I have research collaborations with both Uppsala University, Ahlborg University, Mayo Clinic in the US. The Nordic lymphoma group.

I participate and include patients in clinical trial, phase I, phase II and phase III, mainly within the field of lymphoma and particularily mantle cell lymphoma. We introduce novel targeted drugs, explore immunotherapies and implement new disease monitoring tools.

Research description

My primary research interest is in malignant lymphomas, with a specific focus on Hodgkin lymphoma and Mantle cell lymphoma. In addition, I have an interest in Ovarian and Testicular cancer.

Mantle cell lymphoma (MCL) is one of the lymphoma subtype that with combination chemotherapy still has a poor survival, although prognostic heterogeneity exists. Using epidemiological “real-world data” I investigate treatment selection and the prognostic implication of associated diseases. I am also national principal investigator for the ENRICH-trial: A randomized phase III study for elderly MCL patients with randomization between Rituximab-Ibrutinib AND Rituximab-chemotherapy (Bendamustine or CHOP) with the aim to test if a chemotherapy free concept can improve survival. I am also local PI for the VALERIA trial in Uppsala testing Lenalidomide-Venetoclax and Rituximab for relapsed/refractory mantle cell lymphoma patients. We started in year 2022 the ALTAMIRA trial that investigates a disease monitoring approch with minimal residual disease monitoring for elderly mantle cell lymphoma patients treated with acalabrutinib and rituximab.

In addition, my research interests are in young cancer patients, with a specific focus on survivorship, particularly childbearing potential and long-term prognosis for Hodgkin lymphoma patients, other lymphoma subtypes and testicular cancer. I describe late adverse effects from both chemotherapy and radiotherapy. We have in collaboration with other researcher and specifically Caroline Weibull ( published a series of publications regarding childbearing potential in Hodgkin lymphoma survivors (please see below).

I also study other lymphatic malignancies, testicular cancer and ovarian cancer both regarding aetiology, prognosis and late-effects from treatment.

Teaching portfolio

Teacher Medical School, Oncology, Uppsala University since year 2010

Teacher research school in Epidemiology, Karolinska Institutet 2013-2014

Steering committee National Research School in Oncology, NATION, since 2017

Examiner for project-works in Medical School, Uppsala University since 2017


MD, Uppsala University 2001

PHD, Uppsala University 2009, Hodgkin lymphoma – an interplay between tumour cell and microenvironment 

MD, specialist Internal Medicine 2011

MD, specialist Oncology 2013

Associate Professor in Oncology 2016

Good Clinical Practice, Investigator Site Personnel ICH-GCP 2017

Senior consultant, Oncology 2019

Senior Clinical Investigator Award, the Swedish Cancer Society 2019-2025

Senior lecturer since 2021

Professor Uppsala University 2023